Group's Goal Is to Accelerate Alzheimer's Clinical Trials
INDIANAPOLIS, IN--(Marketwired - Sep 16, 2014) - YourEncore (www.yourencore.com), a company that helps life sciences, consumer products and food companies solve complex innovation, compliance and productivity challenges, is loaning executive Jason Bork to the Global Alzheimer's Platform to act as the group's project management lead.
The Global Alzheimer's Platform (GAP) was launched in February by the Global CEO Initiative (CEOi) on Alzheimer's Disease and the New York Academy of Sciences. GAP's objectives are to reduce the time and costs of Alzheimer's clinical trials by developing a patient registry infrastructure and a pre-qualified network of trial sites that enable innovative trial execution and leverage international collaboration.
Alzheimer's disease is an incurable, progressive brain disease that slowly destroys memory and thinking skills and eventually is fatal. It is the sixth leading cause of death in the United States, according to the Centers for Disease Control and Prevention (CDC). The cost to care for Alzheimer's patients in the United States will exceed $100 billion by 2050, and the global impact is ten-times greater, according to USAgainstAlzheimer's, the organizer of CEOi. However, the scientific understanding of the disease continues to mature and there are several promising drug targets and candidates that potentially could benefit patients worldwide through streamlined development.
"GAP has very aggressive goals focused mainly on accelerating clinical studies of promising drug candidates," said Bork. "We are working quickly to develop a program with a robust, global patient registry. Our plan is to also pre-certify clinical trial sites and implement agreed-upon standards so the time needed to conduct clinical trials is greatly compressed."
"We are very proud to lend our expertise to this important initiative," said Brad Lawson, president of YourEncore. "As part of this private-public partnership, YourEncore will contribute services that will help to coordinate collaboration across pharma, government and other private companies to ensure the group's aggressive goals are met."
As project management lead, Bork will work with pharma partners and GAP leadership, including Eli Lilly & Company vice president, Johanna Carmel Egan, Ph.D., who is co-director of the GAP Program Management Office, along with Luc Truyen, M.D., Ph.D, vice president Neuroscience External Affairs and chair, Johnson & Johnson, Global Fight Against Alzheimer's Disease.
"We are grateful to YourEncore for its important contributions to GAP and support for our efforts to eradicate Alzheimer's Disease," said George Vradenburg, co-founder and chairman of USAgainstAlzheimer's. "Together with executives on loan from Johnson & Johnson and Eli Lilly & Company, Jason Bork will bring industry competence and experience to our efforts."
Prior to Bork's role at YourEncore, he had global responsibilities for project management at Covance Central Laboratories, where he focused on improving capabilities to deliver best practices to more than 200 pharmaceutical and biotech clients. He also spent 13 years at Eli Lilly & Company in project management leadership roles, Product Research and Development (PR&D) and manufacturing.
Bork is a graduate of Rose-Hulman Institute of Technology.
Indianapolis-based YourEncore helps companies in the life sciences, consumer products andfood industries solve complex innovation, compliance and productivity challenges by deploying industry-accomplished experts. YourEncore experts, which include MDs, PhDs, executives and practitioners, have on average 25 years of experience and are behind many of the most successful products on the market. In addition to advisory services, the company also offers the resources to act on its recommendations. Founded in 2003, YourEncore today works with 12 of the 15 leading global pharmaceutical companies and 4 of the 6 top consumer care companies. For more information, visit www.yourencore.com and follow us onFacebook and LinkedIn.